IDEA AG today announced the granting of a new US patent (7,473,432) that covers the recently improved Transfersome technology and the Company’s lead product, Diractin, which is already approved in Switzerland and in the final stage (phase III) of clinical development in Europe and the USA.
The details can be read here.
No comments:
Post a Comment